Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study

• Main Authors: Zhuoling Zheng (Author), Yihong Zhao (Author), Jingwen Xie (Author), Min Gao (Author), Yiting Wang (Author), Xiaoyan Li (Author)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

IntroductionBevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is widely used as a first-line treatment for metastatic colorectal cancer (mCRC), with hypertension being a common adverse effect. However, there is limited data on the predisposing factors contributing to bevacizumab-in...